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The molecular prevalence of human parvovirus B19V (B19V) in bone marrow (BM) samples from 120 cases
with cytopenias of unknown etiology was compared with that in samples from 45 BM donors (control group 1)
and 120 oncohematological patients (control group 2) to determine the role that B19V genotypes may play in
unexplained cytopenias. Of the 285 participants, the BM samples of 39 (13.7%) contained B19V DNA (21 with
genotype 1, 5 with genotype 2, and 13 with genotype 3). The prevalences of B19V were similar between case and
control subjects (15.0% versus 12.7%, respectively). Genotypes 2 and 3 were associated with older age and were
detected in similar proportions between case and control group 2 subjects. The results of this study do not
support a role for B19V genotype variants in the etiology of unexplained cytopenias.
Human parvovirus B19 (B19V), which belongs to the genus
Erythrovirus of the family Parvoviridae, is a tiny single-stranded
DNA virus that propagates in actively dividing erythroid lin-
eage progenitors of bone marrow (BM) and blood, inhibiting
erythropoiesis (1). Comparisons of B19V genomic sequences
from different isolates identified 3 genetically distinct B19V
genotypes with more than 10% genetic variability among them.
These were designated genotype 1 (B19-related viruses), ge-
notype 2 (A6-related viruses), and genotype 3 (V9-related vi-
ruses) (5). Infection with B19V genotype 1 has been associated
with a wide range of human diseases, including erythema in-
fectiosum, arthropathy, transient aplastic crisis, persistent ane-
mia, and hydrops fetalis (6).
We have previously shown that genotype 3 accounts for
approximately 50% of the parvovirus-positive samples in our
center (4); however, the clinical significance of this finding has
not yet been determined. In this study, we aimed to determine
if the presence of B19V genotypes 2 and 3 isolated from BM
cells is associated with cytopenias of unknown etiology.
An unmatched 1:2 case-control study was conducted from
September 2006 to May 2009. Based on the results of our
previous study and on the following assumptions (  0.05;
power 0 to 80; prevalence rate of B19V in patients 17.5%;
odds ratio for B19V infection  2.8; ratio of controls to
cases  2:1), it was determined that a sample size of 122 cases
was needed to demonstrate a link between B19V infection and
cytopenia. Accordingly, for this study, we recruited a total of
120 cases fulfilling the recommended diagnostic criteria for
idiopathic cytopenia. These criteria define idiopathic cytopenia
as cytopenia in one or more cell lineages (i) that persists for at
least 6 months and (ii) that cannot be explained by any other
hematological or nonhematological disease. Two control
groups were chosen to enhance the power of the study. Control
group 1 consisted of 45 BM donors, and group 2 included 120
patients with oncohematological disorders (Table 1). We were
unable to identify two controls for every case, and the total
number of controls was thus limited to 165.
Peripheral blood (PB) (5 ml) and BM samples were col-
lected from all participants. B19V DNA was extracted and
amplified as described previously (4). PCR products were pu-
rified and subsequently sequenced in both directions using the
internal PCR primers. The resultant sequences were aligned
with B19V GenBank sequences that showed high-scoring
matches with our sequences using ClustalX and then analyzed
phylogenetically as previously described (4). The plasma (PL)
samples were tested for the presence of B19V IgM and IgG
using the Biotrin parvovirus B19 IgM and IgG enzyme immu-
noassay kits (Biotrin International Ltd., Dublin, Ireland).
Of the 285 individuals evaluated, 152 (53%) were male and
133 (47%) were female. BM donors were younger (median
age  35 years) than both case patients (median age  55
years) and control group 2 (median age  60 years; P  0.01).
The rates of anemia (hemoglobin less than 11 g/dl), thrombo-
cytopenia (platelet count below 150,000/l), and leukopenia
(total leukocyte count, 4,000 cells/mm3) in the cases were
64%, 54%, and 17%, respectively. In control group 2, the rates
were 39%, 41%, and 2%, respectively.
As shown in Table 1, the B19V partial genome was detected
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in 39 (13.7%) of 285 BM samples and 11 (27.5%) of these had
detectable virus in their peripheral blood. Of these 39 partic-
ipants, 21 (53.9%) were infected with genotype 1, 5 (12.8%)
with genotype 2, and 13 (33.3%) with genotype 3. The overall
prevalences of B19V were similar between cases and controls
(15.0% versus 12.7%, respectively; odds ratio [OR], 1.2; 95%
confidence interval [CI], 0.58 to 2.51, P  0.5). In the 39
medical reports of participants with detectable B19V DNA,
there were 3 cases and 1 neoplastic patient from control group
2 who had blood transfusions before their BM samples were
collected. The prevalences of genotypes 2 and 3 were also
similar between the cases (5.8%) and control group 2 (6.7%;
P  0.7). Genotype 3 was detected only in one specimen from
the BM donor control group by PCR analysis. The prevalences
of circulating B19V were not significantly different between
cases (5.0%) and controls (4.2%; P  0.8).
Based on the serological results shown in Table 2, three
groups were identified: (i) one group of 3 cases with acute or
recent B19V infection (positive test for IgM B19V antibodies
TABLE 1. Demographic characteristics of and parvovirus presence
in the cases and controls according to genotype
Characteristic






Cases 18 (15.0) 11 (9.2) 7 (5.8) 120
Control 1 6 (13.3) 5 (11.1) 1 (2.2) 45
Control 2 15 (12.5) 5 (4.2) 10 (8.3) 120
Gender
Male 20 (13.1) 11 (7.2) 9 (5.9) 152
Female 20 (15.0) 11 (8.2) 9 (6.7) 133
Median age in yrs 55.5 47 62.5a
a Difference between genotypes 2/3 and genotype 1, P  0.01 (Mann-Whitney
test).
TABLE 2. Description of the PCR-positive casesa
Group Sequence ID Age (yr) Sample(s) PCRpositive Genotype Serology (ELISA) result Clinical history
Cases 07BR EC01 36 PB and BM 1 IgM and IgG Pure red cell aplasia, HIV, hepatitis
07BR EC02 61 BM 1 IgG Pancytopenia
07BR EC03 27 BM 1 IgG Anemia, skin rash, arthralgia
07BR EC04 84 BM 3 IgG Pure red cell aplasia
07BR EC05 54 PB and BM 3 IgM and IgG Anemia, skin rash, arthralgia
07BR EC06 53 PB and BM 1 IgM and IgG Pure red cell aplasia, skin rash, arthralgia
07BR EC07 76 BM 3 Negative Anemia, skin rash, arthralgia
07BR EC08 33 BM 1 IgG Leukopenia
07BR EC09 76 BM 1 IgG Thrombocytopenia
07BR EC10 72 BM 2 IgG Thrombocytopenia
07BR EC11 56 BM 1 IgG Anemia, arthralgia
07BR EC12 43 BM 1 IgG Anemia and thrombocytopenia
07BR EC13 87 PB and BM 1 Negative Pancytopenia
07BR EC14 55 PB and BM 3 IgG Thrombocytopenia
07BR EC15 61 PB and BM 1 IgG Anemia, skin rash, hepatitis
07BR EC16 69 BM 2 IgG Thrombocytopenia, skin rash, arthralgia, hepatitis
07BR EC17 62 BM 3 IgG Thrombocytopenia, arthralgia
07BR EC18 53 BM 1 IgG Leukopenia, arthralgia
Group 1 07BR EGP2_01 31 BM 1 IgG Asymptomatic
07BR EGP2_02 30 BM 1 IgG Asymptomatic
07BR EGP2_03 31 BM 1 IgG Asymptomatic
07BR EGP2_04 33 BM 3 IgG Asymptomatic
07BR EGP2_05 51 BM 1 Negative Asymptomatic
07BR EGP2_06 45 BM 1 IgG Asymptomatic
Group 2 07BR EGP3_01 63 PB and BM 3 IgG Non-Hodgkin lymphoma
07BR EGP3_02 74 BM 3 IgG Chronic lymphocytic leukemia
07BR EGP3_03 57 BM 1 IgG Hodgkin lymphoma
07BR EGP3_04 57 BM 1 Negative Hairy cell leukemia
07BR EGP3_05 73 PB and BM 2 Negative Chronic lymphocytic leukemia
07BR EGP3_06 47 PB and BM 3 IgG Chronic myelogenous leukemia
07BR EGP3_07 63 BM 3 IgG Hairy cell leukemia
07BR EGP3_08 56 BM 3 IgG Chronic lymphoproliferative disease
07BR EGP3_09 61 BM 3 Negative Follicular lymphoma
07BR EGP3_10 47 PB and BM 1 IgG Follicular lymphoma
07BR EGP3_11 19 BM 1 IgG Chronic lymphocytic leukemia
07BR EGP3_12 61 BM 3 Negative Myeloproliferative syndrome
07BR EGP3_13 49 BM 2 IgG Chronic lymphocytic leukemia
07BR EGP3_14 73 BM 2 IgG Chronic lymphocytic leukemia
07BR EGP3_15 37 PB and BM 1 IgG Non-Hodgkin lymphoma
a Abbreviations: ID, identification; ELISA, enzyme-linked immunosorbent assay; PB, peripheral blood; BM, bone marrow.
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and a positive result for viral DNA by PCR in PL and BM), (ii)
one group of 6 participants with chronic or persistent B19V
infection (negative test for IgM and a positive B19V PCR in
PL and BM), and (iii) one group of 23 subjects with past or
latent infection (negative IgM, positive IgG, and positive B19V
PCR in BM). Six patients had detectable B19V but were neg-
ative for anti-B19V IgG. In four control group 2 patients
(group 2, Table 2), the failure to develop an antibody response
could be explained by a deterioration of the immune response
due to their primary disease. In the other two cases, age (mean,
81.5 years) could explain the negative IgG results. Alterna-
tively, the absence of IgG antibodies could represent a false-
negative result. Sample contamination cannot be excluded.
However, this is a low probability given the extensive precau-
tions taken during extraction and PCR setup.
In our samples, subjects infected with genotypes 2 and 3
were significantly older than individuals infected with genotype
1 (mean age, 62.5 years versus 47.2 years, respectively; P 
0.01, Mann-Whitney test) (Table 1). These results are very
similar to data collected from central and northern Europe,
suggesting that the circulation of genotype 2 viruses ceased in
the late 1960s and that genotype 1 is now the most prevalent in
those areas (2, 3). Therefore, it is not surprising that we de-
tected genotype 3 in a BM sample from only one BM donor,
whereas genotypes 2 and 3 were present in the samples from
the other 2 groups compared with patients. Unfortunately,
because we were using convenient samples, the control groups
were not fully matched in terms of age, and the BM donors
were younger than the patients in the other 2 groups. A control
population of age-matched controls would have been prefera-
ble for producing a normally shaped sampling distribution.
However, there were practical difficulties in recruiting a suffi-
ciently large control group of representative adult BM donors
not biased for age. Nevertheless, the overall rates of PCR
positivity were quite similar in the 3 groups, suggesting that the
detection of B19V in BM is common for all genotypes and that
these viruses are not the etiologic agent in most cases of cyto-
penia. Although the sample size was too small to draw a de-
finitive conclusion, our results showed that detection of B19V
DNA in plasma samples in cases was similar to that in control
groups. In conclusion, our data suggest that the detection of
B19V in BM is a common event and is likely not related to
most cytopenias of unknown origin. In these patients, PCR
positivity may indicate asymptomatic infection, and such re-
sults should not be used exclusively for specific clinical diag-
nosis and therapeutic orientation. Therefore, measurement of
viral load, which was not performed in our subjects, or detec-
tion of both circulating B19V DNA and anti-B19V IgM may be
a better method for the detection of acute infection.
Nucleotide sequence accession numbers. The sequences of
our isolates were reported to GenBank under accession num-
bers HQ875018 to HQ875056.
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